CFO transition
Stark Focus Group, Inc. CFO transition: Matthew Szot to succeed John Lipman
Stark Focus Group, Inc. reported in a Form 8-K filed September 25, 2026 that Matthew Szot will succeed John Lipman as Chief Financial Officer, effective October 8, 2026.
In the filing's words
On September 21, 2026, the Board of Directors (the “ Board ”) of Stark Focus Group, Inc. (the “ Company ”) unanimously approved the appointment of Matthew Szot to be the Company’s new Chief Financial Officer, effective on October 8, 2026 (the “ Effective Date ”).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Stark Focus Group, Inc. |
|---|---|
| Event | Transition |
| Incoming | Matthew Szot |
| Outgoing | John Lipman |
| Title in the filing | Chief Financial Officer |
| Effective | October 8, 2026 |
| 8-K filed | September 25, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer, Cadrenal Therapeutics, Inc. |
| SEC CIK | 0001794942 |
Stark Focus Group, Inc. reported this change in a Form 8-K, Item 5.02, filed September 25, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Matthew Szot? Send a correction with the primary source.